Redox, immune and genetic biomarker system for personalized treatments in colorectal cancer

doi:10.4251/wjgo.v11.i2.117

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 11, Issue 2

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Supplementary Materials of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (7851)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-7) series, Tables (1-4) series.

Item

Count

PDF

328

WORD

281

HTML

3757

Figures (1-7)

407

Tables (1-4)

255

Sum=5028

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

491

Download

769

Sum=1260

Publishing Process of This Article

Item

Count

Browse

591

Download

972

Sum=1563

Feb 15, 2019 (publication date) through Nov 28, 2024

Times Cited of This Article

Times Cited (3)

Journal Information of This Article

Publication Name

World Journal of Gastrointestinal Oncology

ISSN

1948-5204

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Study

World J Gastrointest Oncol. Feb 15, 2019; 11(2): 117-138
Published online Feb 15, 2019. doi: 10.4251/wjgo.v11.i2.117

Table 1 Levels of cytokines, soluble receptors and redox system molecules in healthy subject adenoma subject and tumor patients groups

	HS	Men	Women	Men vs womendifferences
Trx1	107.6 ± 12.2	124.3 ± 22.7	98.0 ± 14.0	NS
RTrx1	2.2 ± 0.2	2.7 ± 0.4	2.0 ± 0.2	NS
sCD30	8.0 ± 0.7	6.7 ± 0.9	8.9 ± 1.0	NS
TGFβ	14800.0 ± 498.2	15150.2 ± 906.5	14598.3 ± 594.8	NS
IL2	53.6 ± 4.8	42.1 ± 5.7	70.0 ± 8.1	NS
IFNγ	69.4 ± 6.9	53.9 ± 9.6	92.0 ± 9.5	NS
IL4	9.4 ± 0.6	8.0 ± 0.8	11.4 ± 0.9	P < 0.00001
IL6	4.1 ± 0.8	2.7 ± 0.6	5.3 ± 1.5	P = 0.001
IL10	5.2 ± 0.7	4.8 ± 0.5	5.9 ± 1.7	NS
sIL2R	250.0 ± 10.4	238.6 ± 12.5	260.6 ± 16.4	P = 0.00009
sIL6R	70.7 ± 4.0	67.4 ± 6.0	73.5 ± 5.4	NS
	AS
Trx1	649.5 ± 60.6	637.9 ± 112.7	656.7 ± 75.5	NS
RTrx1	3.24 ± 0.27	3.4 ± 0.4	3.1 ± 0.37	NS
sCD30	10.7 ± 2.5	8.5 ± 3.1	12.1 ± 3.7	NS
TGFβ	24474.3 ± 665.8	25050.0 ± 1582.4	24114.5 ± 540.8	NS
IL2	39.9 ± 23.5	19.2 ± 1.4	52.8 ± 38.4	NS
IFNγ	98.3 ± 17.5	130.9 ± 35.3	78.0 ± 16.1	NS
IL4	25.5 ± 4.5	15.2 ± 5.4	31.9 ± 5.5	NS
IL6	6.2 ± 2.1	0.5 ± 0.4	9.8 ± 2.8	NS
IL10	7.1 ± 0.9	7.3 ± 2.1	6.9 ± 1.0	NS
sIL2R	295.9 ± 26.7	285.6 ± 50.2	302.3 ± 32.7	NS
sIL6R	146.2 ± 11.2	154.9 ± 20.2	140.7 ± 13.7	NS
	TP
Trx1	1125.0 ± 72.5	1083.7 ± 104.3	1086.3 ± 108.1	NS
RTrx1	3.5 ± 0.5	3.4 ± 0.6	4.4 ± 1.0	NS
sCD30	18.0 ± 2.8	21.3 ± 2.9	17.8 ± 4.0	NS
TGFβ	65331.7 ± 6852.0	69385.9 ± 7400.6	70296.5 ± 16452.3	NS
IL2	16.1 ± 3.6	11.2 ± 1.9	16.1 ± 2.5	NS
IFNγ	140.0 ± 14.4	135.2 ± 7.2	140.0 ± 11.4	NS
IL4	160.5 ± 20.5	186.2 ± 33.8	151.6 ± 60.5	NS
IL6	140.0 ± 46.0	139.5 ± 50.3	176.1 ± 92.0	NS
IL10	31.4 ± 6.4	37.7 ± 9.1	22.2 ± 5.7	NS
sIL2R	532.2 ± 21.8	545.2 ± 29.0	504.2 ± 44.7	NS

HS vs AS: Trx1 P = 0.009; RTrx1 P = 0.008; TGFβ P = 0.04; IFNγ P = 0.01; IL6 P = 0.0004; IL10 P = 0.002; sIL2R P < 0.00001; sIL6R P ≤ 0.00001; HS vs TP: Trx1 P < 0.00001; RTrx1 P < 0.00001; sCD30 P < 0.00001; TGFβ P < 0.00001; IL2 P < 0.00001; IFNγ P < 0.00001; IL4 P < 0.00001; IL6 P < 0.00001; IL10 P < 0.00001; sIL2R P < 0.00001; sIL6R P < 0.00001; IL10 P < 0.00001; sIL2R P < 0.00001; sIL6R P < 0.00001. HS: Healthy subject; AS: Adenoma subject; TP: Tumor patients.

Citation: Berghella AM, Aureli A, Canossi A, Beato TD, Colanardi A, Pellegrini P. Redox, immune and genetic biomarker system for personalized treatments in colorectal cancer. World J Gastrointest Oncol 2019; 11(2): 117-138
URL: https://www.wjgnet.com/1948-5204/full/v11/i2/117.htm
DOI: https://dx.doi.org/10.4251/wjgo.v11.i2.117